AR128311A1 - Inmunización activa para reducir el dolor osteoarticular, neuropático y en cáncer - Google Patents
Inmunización activa para reducir el dolor osteoarticular, neuropático y en cáncerInfo
- Publication number
- AR128311A1 AR128311A1 ARP230100133A ARP230100133A AR128311A1 AR 128311 A1 AR128311 A1 AR 128311A1 AR P230100133 A ARP230100133 A AR P230100133A AR P230100133 A ARP230100133 A AR P230100133A AR 128311 A1 AR128311 A1 AR 128311A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- pain
- fusion protein
- active immunization
- osteoarticular
- Prior art date
Links
- 230000003053 immunization Effects 0.000 title abstract 2
- 238000002649 immunization Methods 0.000 title abstract 2
- 206010058019 Cancer Pain Diseases 0.000 title 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 title 1
- 208000004296 neuralgia Diseases 0.000 title 1
- 230000002981 neuropathic effect Effects 0.000 title 1
- 208000021722 neuropathic pain Diseases 0.000 title 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 3
- 201000008482 osteoarthritis Diseases 0.000 abstract 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 abstract 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 abstract 2
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 2
- 102000015336 Nerve Growth Factor Human genes 0.000 abstract 2
- 102400000096 Substance P Human genes 0.000 abstract 2
- 101800003906 Substance P Proteins 0.000 abstract 2
- 229940053128 nerve growth factor Drugs 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una proteína de fusión recombinante utilizada para la inmunización activa o vacuna en el tratamiento del dolor en un sujeto y un método para la producción de esta. La proteína de fusión recombinante incluye: un factor de crecimiento nervioso (NGF); y sustancia P (SP) o un péptido relacionado con el gen de la calcitonina (CGRP). El dolor puede estar asociado con la osteoartritis (OA), inflamación neurogénica, neuropatía, artritis reumatoide, post-cirugía o cáncer. La invención es particularmente útil para tratar el dolor de OA en animales. Reivindicación 17: El vector recombinante de la reivindicación 16, que comprende una secuencia de ácido nucleico que tiene al menos un 90%, al menos un 95% o al menos un 99% de identidad de secuencia con SEC ID Nº 22, SEC ID Nº 23, SEC ID Nº 24 o SEQ ID Nº 25. Reivindicación 22: Una composición inmunogénica que comprende al menos una proteína de fusión recombinante de cualquiera de las reivindicaciones 1 - 15.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263301873P | 2022-01-21 | 2022-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128311A1 true AR128311A1 (es) | 2024-04-17 |
Family
ID=85157093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100133A AR128311A1 (es) | 2022-01-21 | 2023-01-20 | Inmunización activa para reducir el dolor osteoarticular, neuropático y en cáncer |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR128311A1 (es) |
| AU (1) | AU2023208958A1 (es) |
| WO (1) | WO2023139542A1 (es) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE77033B1 (en) * | 1989-08-16 | 1997-11-19 | Univ Tulane | Substance P antagonists |
| ME00226B (me) * | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| EP3842458A1 (en) * | 2005-11-14 | 2021-06-30 | Teva Pharmaceuticals International GmbH | Antagonist antibodies directed against calcitonin gene-related peptide |
| BRPI0821383A2 (pt) * | 2007-12-20 | 2015-06-16 | Cytos Biotechnology Ag | Conjugados de ngf e usos dos mesmos |
| NZ595021A (en) * | 2009-03-12 | 2013-04-26 | Nordic Bioscience As | Treatment of diabetes and metabolic syndrome with enteral formulations of calcitonin peptides or calcitonin receptor agonists |
| KR20100136633A (ko) * | 2009-06-19 | 2010-12-29 | 서울대학교산학협력단 | 개의 베타-신경 성장 인자 및 이를 함유하는 개의 신경손상 관련 질환 치료용 수의학적 조성물 |
| JP6629069B2 (ja) * | 2012-06-06 | 2020-01-15 | ゾエティス・エルエルシー | イヌ化抗ｎｇｆ抗体およびその方法 |
| CN109803977B (zh) * | 2016-08-17 | 2023-03-17 | 菲克特生物科学股份有限公司 | 核酸产品及其施用方法 |
| CN113574073A (zh) * | 2018-12-31 | 2021-10-29 | 联脑科学有限公司 | 针对降钙素基因相关肽(cgrp)的肽免疫原及其用于预防和治疗偏头痛的制剂 |
-
2023
- 2023-01-20 AR ARP230100133A patent/AR128311A1/es unknown
- 2023-01-20 WO PCT/IB2023/050517 patent/WO2023139542A1/en active Application Filing
- 2023-01-20 AU AU2023208958A patent/AU2023208958A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023208958A1 (en) | 2024-08-29 |
| WO2023139542A1 (en) | 2023-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022013121A2 (es) | Vacuna 2019-ncov (sars-cov-2) | |
| BR112021024786A2 (pt) | Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada | |
| PH12021500010A1 (en) | Nucleic acid molecules and uses thereof for non-viral gene therapy | |
| PE20220283A1 (es) | Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un medicamento | |
| PT87562A (pt) | Procede de expression de la proapolipoproteine a-i humaine | |
| AR112057A1 (es) | Vectores virales que codifican variantes de fix recombinantes con mayor expresión para la terapia génica de hemofilia b | |
| AR128311A1 (es) | Inmunización activa para reducir el dolor osteoarticular, neuropático y en cáncer | |
| CN114316030B (zh) | 一种透皮吸收性的i型重组胶原蛋白及其用途 | |
| BR112022014552A2 (pt) | Polipeptídeo recombinante, composição farmacêutica, método de prevenção ou tratamento de uma infecção viral em um indivíduo que necessita do mesmo, molécula de rna, composição terapêutica, sistema de expressão, polipeptídeo recombinante para tratar infecção por sars-cov-2 e polinucleotídeo que codifica o polipeptídeo recombinante | |
| CO2023009633A2 (es) | Efecto sinérgico de smn1 y mir-23a en el tratamiento de la atrofia muscular espinal | |
| AR123788A1 (es) | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas | |
| EP3916005A3 (en) | Immunogenic composition | |
| Sandee et al. | Combination of Dsb coexpression and an addition of sorbitol markedly enhanced soluble expression of single‐chain Fv in Escherichia coli | |
| PE20230487A1 (es) | Variantes de alfa-galactosidasa humana | |
| KR20160055940A (ko) | 단백질 추출 방법 | |
| PE20240915A1 (es) | Composiciones y metodos para tratar la enfermedad de fabry | |
| PE20230826A1 (es) | Peptidos y combinaciones de peptidos para uso en inmunoterapia contra la infeccion por sars-cov-2 | |
| PE20221663A1 (es) | Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano | |
| PE20241621A1 (es) | Composiciones de polinucleotidos y sus usos | |
| Piez et al. | Homology between the α1 and α2 chains of collagen | |
| BR112022004601A2 (pt) | Sequências de extensão n-terminal para expressão de peptídeos terapêuticos recombinantes | |
| AR126464A1 (es) | Agentes para el tratamiento de cánceres positivos para cldn6 | |
| EP3263710A1 (en) | Production of activated clostridial neurotoxins | |
| AR126727A1 (es) | Composición y método para tratar la neuropatía óptica hereditaria de leber causada por la mutación nd4 | |
| MX2023002080A (es) | Vector de poxviridae recombinante que expresa moleculas coestimuladoras. |